Compositions and methods of inhibiting n-acylethanolamine-hydrolyzing acid amidase
US-2016256432-A1 · Sep 8, 2016 · US
US9908848B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9908848-B2 |
| Application number | US-201514853697-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 14, 2015 |
| Priority date | Mar 15, 2013 |
| Publication date | Mar 6, 2018 |
| Grant date | Mar 6, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Described herein are compounds and pharmaceutical compositions which inhibit N-acylethanolamine acid amidase (NAAA). Described herein are methods for synthesizing the compounds set forth herein and methods for formulating these compounds as pharmaceutical compositions which include these compounds. Also described herein are methods of inhibiting NAAA in order to sustain the levels of palmitoylethanolamide (PEA) and other N-acylethanolamines (NAE) that are substrates for NAAA, in conditions characterized by reduced concentrations of NAE. Also, described here are methods of treating and ameliorating pain, inflammation, inflammatory diseases, and other disorders in which modulation of fatty acid ethanolamides is clinically or therapeutically relevant or in which decreased levels of NAE are associated with the disorder.
Opening claim text (preview).
What is claimed is: 1. A compound having the structure of Formula I: wherein: R 1 and R 2 are each independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, arylalkyl, and cycloalkylalkyl; or R 1 and R 2 form a cycloalkyl substituent together with the carbon to which they are attached; R 3 is selected from the group consisting of hydrogen and alkyl; wherein R 4 -R 5 -R 6 is an alkyl selected from the group consisting of unsubstituted octyl, unsubstituted nonyl, unsubstituted decyl, methyl substituted with an unsubstituted cyclohexyl, ethyl substituted with an unsubstituted cyclohexyl, propyl substituted with an unsubstituted cyclohexyl, butyl substituted with an unsubstituted cyclohexyl, pentyl substituted with an unsubstituted cyclohexyl, hexyl substituted with an unsubstituted cyclohexyl, heptyl substituted with an unsubstituted cyclohexyl, octyl substituted with an unsubstituted cyclohexyl, nonyl substituted with an unsubstituted cyclohexyl and docyl substituted with an unsubstituted cyclohexyl; or a pharmaceutically acceptable salt or ester thereof. 2. A compound of claim 1 , having the structure: 3. A compound of claim 1 , wherein R 1 and R 2 are both hydrogen. 4. A compound of claim 1 , wherein R 1 is hydrogen and R 2 is methyl. 5. A compound of claim 1 , wherein the compound is selected from the group consisting of 6. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, carrier or diluent. 7. A compound of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 8. A compound of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof.
with a nitrogen atom directly attached in position 3 · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.